CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,510 | +43.8% | 5,668 | +5.6% | 0.00% | +33.3% |
| Q2 2023 | $58,780 | +208.2% | 5,368 | -12.5% | 0.00% | +200.0% |
| Q1 2022 | $19,071 | -73.9% | 6,132 | -69.4% | 0.00% | 0.0% |
| Q3 2021 | $73,150 | -28.1% | 20,041 | -10.5% | 0.00% | -50.0% |
| Q1 2021 | $101,710 | +66.9% | 22,403 | +111.1% | 0.00% | +100.0% |
| Q4 2020 | $60,924 | -43.4% | 10,614 | -28.6% | 0.00% | -50.0% |
| Q3 2020 | $107,666 | +28.2% | 14,871 | -38.2% | 0.00% | +100.0% |
| Q2 2020 | $84,015 | -20.3% | 24,073 | +16.9% | 0.00% | -50.0% |
| Q3 2019 | $105,467 | -26.0% | 20,599 | +3.5% | 0.00% | 0.0% |
| Q2 2019 | $142,484 | -46.1% | 19,900 | 0.0% | 0.00% | -60.0% |
| Q1 2019 | $264,272 | +68.7% | 19,900 | 0.0% | 0.01% | +66.7% |
| Q4 2018 | $156,613 | -29.0% | 19,900 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $220,492 | -99.9% | 19,900 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $267,058,000 | – | 19,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |